Radiation therapy followed by intrathecal trastuzumab and pertuzumab for HER2+ breast leptomeningeal disease is safe

JAMA Oncology shared a post on X about a recent paper by Kamran Ahmed et al. published in JAMA Oncology.

“Radiation Therapy Followed by Intrathecal Trastuzumab-Pertuzumab for ERBB2-Positive Breast Leptomeningeal Disease: A Phase 1 Nonrandomized Controlled Trial”

Authors: Kamran Ahmed, Priya Kumthekar, Yolanda Pina, Youngchul Kim, Michael Vogelbaum, Hyo Han, Peter Forsyth

“Radiation therapy followed by intrathecal trastuzumab and pertuzumab for HER2+ breast leptomeningeal disease is safe with initial intracranial control results that appear encouraging.”

Melvin Chua, Head of the Department of Head Neck and Thoracic Cancers at the National Cancer Centre Singapore, shared this post, adding:

“Fascinating! With promising results for this group of very poor players.”

Source: JAMA Oncology/X and Melvin Chua/X